Watson confirms Actavis acquisition in deal set to take group revenues to $8bn this year
This article was originally published in Scrip
Executive Summary
With an upfront payment of €4.25 billion ($5.6 billion) and up to €250 million in future common stock to acquire the private Swiss firm Actavis Group, Watson Pharmaceuticals is now the third largest global generics company with anticipated 2012 pro forma revenues of $8 billion.
You may also be interested in...
Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
Septerna Emerges With $100m To Target Undruggable GPCRs
Septerna’s platform purifies G-coupled protein receptors (GPCR) to identify new drug targeting sites and then uses technologies such as machine learning to find novel compounds against hard-to-reach GPCRs.
Immunocore Ready For First-Ever Launch After Kimmtrak’s US Approval
The median pre-discount cost of Kimmtrak – the first approved TCR therapy and the first drug cleared for metastatic uveal melanoma – is $430,000, but the company says payers see the product’s value.